Market News & Trends
Sermonix Pharmaceuticals & Quantum Leap Healthcare Announce New Study Arm to Evaluate Lasofoxifene in Ongoing I-SPY 2 Clinical Trial
Sermonix Pharmaceuticals Inc. and Quantum Leap Healthcare Collaborative recently announced Sermonix’s investigational next-generation targeted endocrine therapy, lasofoxifene, will be evaluated in a new study arm…
Vaxxas Initiates Phase 1 Clinical Study of First Needle-Free, Inactivated Seasonal Influenza Vaccine Quadrivalent Delivered Using High-Density Microarray Patch
Vaxxas recently announced the initiation of a Phase 1 clinical trial with the first needle-free inactivated seasonal influenza vaccine quadrivalent (IIV4) candidate delivered using Vaxxas’…
EuMentis Therapeutics Inc. Receives $3-Million Award from US DoD to Advance its Novel NMDA Receptor Antagonist for Traumatic Brain Injury
EuMentis Therapeutics Inc. recently announced it has received an award from the United States Department of Defense (DoD) to develop a novel small molecule therapeutic…
Bayer Announces First Patients Enrolled in Global Phase 3 Studies for Investigational Oral FXIa Inhibitor Asundexian
Bayer recently announced the first patients have been enrolled in the initial trials for its OCEANIC clinical trial program, designed to explore the use of…
Syneos Health & Haystack Health Partner to Accelerate Clinical Trials With AI
Syneos Health recently announced a strategic partnership with Haystack Health, a Roivant Health portfolio company developing advanced Artificial Intelligence (AI) and Natural Language Processing (NLP) solutions,…
Indaptus Therapeutics Activates Morristown Medical Center as Trial Site in INDP-D101, Its Ongoing Phase 1 Open Label Clinical Trial of Decoy20 in Patients With Advanced Solid Tumors
Indaptus Therapeutics, Inc. recently announced the addition of Morristown Medical Center, part of the Atlantic Health System, as a new clinical trial site for INDP-D101,…
Endogena Therapeutics Receives Fast Track Designation for EA-2353 for the Treatment of Retinitis Pigmentosa
Endogena Therapeutics Inc. recently announced the US FDA has designated the investigation of EA-2353 for the treatment of retinitis pigmentosa (RP) as a Fast Track…
Immutep Reaches Enrolment Target for INSIGHT-003 Trial in 1st Line NSCLC
Immutep Limited recently announced the investigator-initiated INSIGHT-003 trial has reached its enrolment target of 20 patients with 1L NSCLC. INSIGHT-003 is the first trial evaluating…
BD Introduces High-Throughput Single-Cell Multiomics Platform to Expand Scope of Scientific Discovery
BD (Becton, Dickinson and Company) recently announced a new instrument for single-cell multiomics analysis that will enable scientists to run high-throughput studies without sacrificing sample…
First Wave BioPharma Announces First Patient Screened for Phase 2 SPAN Adrulipase Trial in Cystic Fibrosis
First Wave BioPharma, Inc. recently announced the first patient was screened for the Phase 2 SPAN clinical trial investigating an enhanced enteric microgranule delivery formulation…
EXCLUSIVE ONLINE CONTENT
Molex Expands European Manufacturing Footprint & Capabilities With State-of-the-Art Campus in Poland
Molex recently announced a major expansion of its global manufacturing footprint with the opening of a new campus in Katowice, Poland. The facility’s initial 23,000-square-meter manufacturing space will….
Kala Pharmaceuticals Completes Sale of EYSUVIS & INVELTYS to Alcon Inc
Kala Pharmaceuticals, Inc. recently announced it has completed the sale of its commercial portfolio and related intellectual property assets to Alcon Inc., a transaction that was….
Insightful Science Acquires Protein Metrics to Expand its R&D Solution to Include Proteomics
Insightful Science recently announced it has completed the transaction to acquire Protein Metrics, Inc. to expand the company’s R&D value chain to widen the biopharmaceutical protein analysis arena….
Acer Therapeutics & Relief Therapeutics Announce NDA Submission for ACER-001 for Treatment of Urea Cycle Disorders
Acer Therapeutics Inc. Relief Therapeutics recently announced the submission of a New Drug Application (NDA) to the US FDA for ACER-001 (sodium phenylbutyrate) for the treatment of Urea Cycle Disorders (UCDs)….